Compare equities side by side
Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Coloplast is a Danish medical device manufacturer specializing in ostomy care (stoma bags and accessories), continence care (catheters, urological products), and wound & skin care products. The company operates globally with strong market positions in Europe (~50% of revenue) and North America (~30%), serving aging demographics with chronic conditions requiring long-term consumable medical supplies. The business model centers on recurring revenue from consumable products with high switching costs due to patient-clinician relationships and product familiarity.
Coloplast generates revenue through recurring sales of consumable medical supplies to patients with chronic conditions requiring lifelong product use. The company maintains pricing power through product differentiation (hydrocolloid adhesives, compact designs), direct-to-patient distribution channels that build loyalty, and reimbursement relationships with national healthcare systems and private insurers. Gross margins of 65% reflect manufacturing scale in Denmark and Hungary, proprietary materials technology, and limited generic competition due to regulatory barriers and patient preference for established brands. The company invests heavily in clinical education and patient support programs to drive product adoption and retention.
Organic revenue growth rates in core markets (target: mid-single digits), particularly ostomy care volume trends in Europe and North America
Market share gains in continence care, especially intermittent catheter penetration in the US where Coloplast competes against Hollister and Teleflex
Operating margin expansion or contraction driven by manufacturing efficiency, pricing dynamics, and currency headwinds (DKK/USD, DKK/EUR)
New product launches and clinical trial results for innovative ostomy and continence solutions
Healthcare reimbursement policy changes in key markets (Medicare/Medicaid in US, national health systems in Europe)
Healthcare reimbursement pressure as governments seek to control medical device spending through competitive bidding, reference pricing, or formulary restrictions
Aging product portfolio risk if innovation pipeline fails to deliver differentiated solutions as patents expire on key adhesive technologies and competitors introduce lower-cost alternatives
Regulatory intensification including EU Medical Device Regulation compliance costs and potential FDA scrutiny on direct-to-consumer marketing practices
Market share erosion from ConvaTec, Hollister, and B. Braun in ostomy care, particularly in price-sensitive emerging markets
Disruptive technologies in continence care such as implantable neuromodulation devices (Medtronic, Axonics) that could reduce catheter demand for certain patient populations
Private label and generic competition in wound care where product differentiation is lower than ostomy/continence segments
Elevated leverage (Debt/Equity 1.87) limits financial flexibility for M&A or share buybacks if operating performance deteriorates
Currency exposure with ~30% revenue in USD and ~20% in GBP creates earnings volatility when DKK strengthens
Pension obligations in Denmark subject to discount rate sensitivity, though not disclosed in available data
low - Medical device consumables for chronic conditions exhibit minimal GDP sensitivity as patients require continuous product use regardless of economic conditions. Healthcare spending is non-discretionary, and reimbursement from government and private insurers insulates demand. However, elective procedures (wound care related to surgeries) show modest cyclicality during severe recessions.
Rising rates create moderate headwinds through higher financing costs on the company's debt (Debt/Equity of 1.87) and valuation multiple compression for defensive healthcare stocks as bond yields become more attractive. Currency effects also matter: higher US rates strengthen USD, creating translation headwinds for DKK-reporting Coloplast with significant USD revenue. However, the business fundamentals remain largely insulated from rate changes.
Minimal direct credit exposure. Revenue is primarily reimbursed by government healthcare systems and large insurers with strong credit profiles. Patient out-of-pocket costs are typically small, limiting bad debt risk. The company's own creditworthiness supports access to capital markets for refinancing.
dividend - The company attracts income-focused investors seeking stable cash flows from defensive healthcare exposure. The 34% FCF yield and recurring revenue model appeal to investors prioritizing capital returns over growth. However, recent 30% stock decline and negative earnings growth suggest value investors may be assessing entry points, while growth investors have rotated out due to slowing organic growth (3% revenue growth vs. historical mid-single digits).
low - Medical device consumables exhibit below-market volatility due to non-cyclical demand and predictable cash flows. However, the recent 30% decline indicates elevated volatility from company-specific challenges (margin pressure, competitive dynamics) rather than systematic risk. Historical beta likely in 0.6-0.8 range for defensive healthcare.
